Status:

Red

Decision Date:

September 2021

Comments

Monotherapy for the treatment of adults with recurrent or advanced mismatch repair deficient/microsatellite instability-high endometrial cancer that has progressed on or following prior treatment with a platinum‑containing regimen. 

RED: 

• NICE TA779: Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency.  (Decision April 2022).

Red Drug Classifications

• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again